Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
It’s the second approved use for Emgality, which first won U.S. approval last fall to treat migraines. Analysts predict it could become a blockbuster.
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Indianapolis-based Lilly reported first quarter revenue of $5.09 billion, up 3% from a year ago but below analyst expectations of $5.2 billion. Sales of several of Lilly’s top drugs missed expectations.
Kansas-based Aratana Therapeutics has three treatments approved by the U.S. Food and Drug Administration and is working on drugs for a range of disease fields, including cancer.
The city’s newest park is springing up on the south side of downtown, a district quickly filling up with apartments, offices and retail—and a noticeable shortage of public green space.
Indianapolis-based Eli Lilly and Co. was one of the first drug firms to begin sharing prices. Now, others are following suit.
Long a leader in diabetes and neuroscience drugs, Eli Lilly and Co. is pushing hard and spending record sums to turbocharge its oncology business, potentially a huge growth area.
As Congress and President Donald Trump's administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome.
The proposed tax abatement is related to a $91 million investment the company is making in a building at the Lilly Technology Center on Kentucky Avenue.
The move comes at a time drug makers, especially those that make insulin, are facing withering criticism for raising prices.
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions
When the Indianapolis-based drug giant made its initial offer Dec. 20, it said it wanted to seal the deal before the J.P. Morgan Healthcare Conference, which ran Jan. 7-10 in San Francisco.
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
